Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns

John P. Kinsella, Gary R. Cutter, Robin H Steinhorn, Leif D. Nelin, William F. Walsh, Neil N. Finer, Steven H. Abman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective To assess the efficacy and safety of early, noninvasive inhaled nitric oxide (iNO) therapy in premature newborns who do not require mechanical ventilation. Study design We performed a multicenter randomized trial including 124 premature newborns who required noninvasive supplemental oxygen within the first 72 hours after birth. Newborns were stratified into 3 different groups by birth weight (500-749, 750-999, 1000-1250 g) prior to randomization to iNO (10 ppm) or placebo gas (controls) until 30 weeks postmenstrual age. The primary outcome was a composite of death or bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age. Secondary outcomes included the need for and duration of mechanical ventilation, severity of BPD, and safety outcomes. Results There was no difference in the incidence of death or BPD in the iNO and placebo groups (42% vs 40%, P =.86, relative risk = 1.06, 0.7-1.6). BPD severity was not different between the treatment groups. There were no differences between the groups in the need for mechanical ventilation (22% vs 23%; P =.89), duration of mechanical ventilation (9.7 vs 8.4 days; P =.27), or safety outcomes including severe intracranial hemorrhage (3.4% vs 6.2%, P =.68). Conclusions We found that iNO delivered noninvasively to premature infants who have not progressed to early respiratory failure is a safe treatment, but does not decrease the incidence or severity of BPD, reduce the need for mechanical ventilation, or alter the clinical course.

Original languageEnglish (US)
Pages (from-to)1104-1108.e1
JournalJournal of Pediatrics
Volume165
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Bronchopulmonary Dysplasia
Artificial Respiration
Nitric Oxide
Newborn Infant
Safety
Placebos
Intracranial Hemorrhages
Incidence
Random Allocation
Birth Weight
Premature Infants
Respiratory Insufficiency
Multicenter Studies
Therapeutics
Gases
Parturition
Oxygen

Keywords

  • BPD Bronchopulmonary dysplasia CPAP Continuous positive airway pressure iNO Inhaled nitric oxide NO Nitric oxide PH Pulmonary hypertension PMA Postmenstrual age

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Kinsella, J. P., Cutter, G. R., Steinhorn, R. H., Nelin, L. D., Walsh, W. F., Finer, N. N., & Abman, S. H. (2014). Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. Journal of Pediatrics, 165(6), 1104-1108.e1. https://doi.org/10.1016/j.jpeds.2014.06.018

Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. / Kinsella, John P.; Cutter, Gary R.; Steinhorn, Robin H; Nelin, Leif D.; Walsh, William F.; Finer, Neil N.; Abman, Steven H.

In: Journal of Pediatrics, Vol. 165, No. 6, 01.12.2014, p. 1104-1108.e1.

Research output: Contribution to journalArticle

Kinsella, John P. ; Cutter, Gary R. ; Steinhorn, Robin H ; Nelin, Leif D. ; Walsh, William F. ; Finer, Neil N. ; Abman, Steven H. / Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. In: Journal of Pediatrics. 2014 ; Vol. 165, No. 6. pp. 1104-1108.e1.
@article{6643d271297244b9980a7fc508707a30,
title = "Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns",
abstract = "Objective To assess the efficacy and safety of early, noninvasive inhaled nitric oxide (iNO) therapy in premature newborns who do not require mechanical ventilation. Study design We performed a multicenter randomized trial including 124 premature newborns who required noninvasive supplemental oxygen within the first 72 hours after birth. Newborns were stratified into 3 different groups by birth weight (500-749, 750-999, 1000-1250 g) prior to randomization to iNO (10 ppm) or placebo gas (controls) until 30 weeks postmenstrual age. The primary outcome was a composite of death or bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age. Secondary outcomes included the need for and duration of mechanical ventilation, severity of BPD, and safety outcomes. Results There was no difference in the incidence of death or BPD in the iNO and placebo groups (42{\%} vs 40{\%}, P =.86, relative risk = 1.06, 0.7-1.6). BPD severity was not different between the treatment groups. There were no differences between the groups in the need for mechanical ventilation (22{\%} vs 23{\%}; P =.89), duration of mechanical ventilation (9.7 vs 8.4 days; P =.27), or safety outcomes including severe intracranial hemorrhage (3.4{\%} vs 6.2{\%}, P =.68). Conclusions We found that iNO delivered noninvasively to premature infants who have not progressed to early respiratory failure is a safe treatment, but does not decrease the incidence or severity of BPD, reduce the need for mechanical ventilation, or alter the clinical course.",
keywords = "BPD Bronchopulmonary dysplasia CPAP Continuous positive airway pressure iNO Inhaled nitric oxide NO Nitric oxide PH Pulmonary hypertension PMA Postmenstrual age",
author = "Kinsella, {John P.} and Cutter, {Gary R.} and Steinhorn, {Robin H} and Nelin, {Leif D.} and Walsh, {William F.} and Finer, {Neil N.} and Abman, {Steven H.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.jpeds.2014.06.018",
language = "English (US)",
volume = "165",
pages = "1104--1108.e1",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns

AU - Kinsella, John P.

AU - Cutter, Gary R.

AU - Steinhorn, Robin H

AU - Nelin, Leif D.

AU - Walsh, William F.

AU - Finer, Neil N.

AU - Abman, Steven H.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective To assess the efficacy and safety of early, noninvasive inhaled nitric oxide (iNO) therapy in premature newborns who do not require mechanical ventilation. Study design We performed a multicenter randomized trial including 124 premature newborns who required noninvasive supplemental oxygen within the first 72 hours after birth. Newborns were stratified into 3 different groups by birth weight (500-749, 750-999, 1000-1250 g) prior to randomization to iNO (10 ppm) or placebo gas (controls) until 30 weeks postmenstrual age. The primary outcome was a composite of death or bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age. Secondary outcomes included the need for and duration of mechanical ventilation, severity of BPD, and safety outcomes. Results There was no difference in the incidence of death or BPD in the iNO and placebo groups (42% vs 40%, P =.86, relative risk = 1.06, 0.7-1.6). BPD severity was not different between the treatment groups. There were no differences between the groups in the need for mechanical ventilation (22% vs 23%; P =.89), duration of mechanical ventilation (9.7 vs 8.4 days; P =.27), or safety outcomes including severe intracranial hemorrhage (3.4% vs 6.2%, P =.68). Conclusions We found that iNO delivered noninvasively to premature infants who have not progressed to early respiratory failure is a safe treatment, but does not decrease the incidence or severity of BPD, reduce the need for mechanical ventilation, or alter the clinical course.

AB - Objective To assess the efficacy and safety of early, noninvasive inhaled nitric oxide (iNO) therapy in premature newborns who do not require mechanical ventilation. Study design We performed a multicenter randomized trial including 124 premature newborns who required noninvasive supplemental oxygen within the first 72 hours after birth. Newborns were stratified into 3 different groups by birth weight (500-749, 750-999, 1000-1250 g) prior to randomization to iNO (10 ppm) or placebo gas (controls) until 30 weeks postmenstrual age. The primary outcome was a composite of death or bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age. Secondary outcomes included the need for and duration of mechanical ventilation, severity of BPD, and safety outcomes. Results There was no difference in the incidence of death or BPD in the iNO and placebo groups (42% vs 40%, P =.86, relative risk = 1.06, 0.7-1.6). BPD severity was not different between the treatment groups. There were no differences between the groups in the need for mechanical ventilation (22% vs 23%; P =.89), duration of mechanical ventilation (9.7 vs 8.4 days; P =.27), or safety outcomes including severe intracranial hemorrhage (3.4% vs 6.2%, P =.68). Conclusions We found that iNO delivered noninvasively to premature infants who have not progressed to early respiratory failure is a safe treatment, but does not decrease the incidence or severity of BPD, reduce the need for mechanical ventilation, or alter the clinical course.

KW - BPD Bronchopulmonary dysplasia CPAP Continuous positive airway pressure iNO Inhaled nitric oxide NO Nitric oxide PH Pulmonary hypertension PMA Postmenstrual age

UR - http://www.scopus.com/inward/record.url?scp=84912561585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912561585&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2014.06.018

DO - 10.1016/j.jpeds.2014.06.018

M3 - Article

VL - 165

SP - 1104-1108.e1

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 6

ER -